Amgen 2Q Revenues: $4.7 billion (+5%) 2Q Earnings: $1.3 billion (-1%) YTD Revenues: $8.7 billion (+8%) YTD Earnings: $2.7 billion (+10%) Comments: Combined Neulasta and Neupogen sales increased 7% to $1.4 billion in the quarter. Enbrel sales increased 9% to $1.2 billion. Sensipar/Mimpara sales increased 12% to $259 million. XGEVA sales increased 39% to $249 million and Prolia sales increased 57% to $188 million. Aranesp sales decreased 2% to $524 million and Epogen sales were down 4% to $50...